Palmatine ameliorates MASLD in type 2 diabetes by modulating hepatic apoptosis and inflammation - PubMed
3 hours ago
- #Palmatine
- #T2DM
- #MASLD
- Palmatine, an isoquinoline alkaloid, shows promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) by modulating hepatic apoptosis and inflammation.
- A multi-omics bioinformatics approach identified five core targets (ADRB2, BCL3, EGR1, FOS, MAP3K8) for palmatine, with molecular docking predicting strong binding.
- Experimental validation in a T2DM-associated MASLD rat model demonstrated palmatine's efficacy in improving liver function, reducing inflammation and oxidative stress, and ameliorating glycolipid metabolism.
- Palmatine treatment also reduced hepatic steatosis and fibrosis, downregulated the five key targets, and suppressed apoptotic executers (Caspase-3, Caspase-8, GSDME).
- The study provides a hypothesis-driven preclinical foundation for palmatine's therapeutic development in MASLD, highlighting its multi-target mechanisms.